Is Enfortumab a targeted drug or an immunosuppressant?

Enfortumab is a targeted drug, not an immunosuppressant. Although ennosumab plays an important role in the treatment of urothelial cancer, its mechanism of action is mainly by binding to the Nectin-4 target, releasing cytotoxins and causing cancer cell apoptosis, rather than inhibiting the growth and spread of cancer cells by regulating the immune system.

1.Targeted drugs: Ennosumab is a targeted therapy drug that works by binding to theNectin-4target, a protein that is overexpressed in a variety of cancers, including urothelial carcinoma. Ennosumab has the ability to selectively bind to Nectin-4, thereby specifically killing cancer cells while causing less damage to healthy tissue.

2.Release cytotoxins: Once ennosumab binds to Nectin-4, it will enter cancer cells and release cytotoxins, leading to apoptosis and death of cancer cells. This specific release of cytotoxins against cancer cells is a key step in the action of ennozumab, which inhibits tumor growth and spread by directly killing cancer cells.

3.Non-immunomodulatory effects: Although ennosumab can kill cancer cells through specific cytotoxic release, it does not achieve its therapeutic effect by regulating the immune system. Unlike immunosuppressants, ennosumab does not directly affect the patient's immune system, but acts directly on cancer cells to inhibit the growth and spread of cancer cells.

In summary, ennosumab is a targeted drug. Its mechanism of action is mainly to bind to the Nectin-4 target, release cytotoxins, and cause cancer cell apoptosis, rather than inhibiting the growth and spread of cancer cells through immune regulation. This targeted therapy strategy is highly selective and specific, can reduce damage to normal tissues while improving the killing effect on cancer cells, and is a promising cancer treatment strategy.